Image 2_Evaluating the efficacy and safety of tebentafusp in the treatment of metastatic uveal melanoma: a 2025 update systematic review and meta-analysis.tif
Background<p>Metastatic uveal melanoma (mUM) is an aggressive malignancy with a dismal prognosis, posing a severe threat to patients’ survival and quality of life. In recent years, tebentafusp, a novel immunotherapeutic agent, has demonstrated promising potential in the management of mUM. Howe...
Saved in:
| Main Author: | Yanlin Wang (110566) (author) |
|---|---|
| Other Authors: | Wen Sun (273647) (author), Bing Wang (126120) (author) |
| Published: |
2025
|
| Subjects: | |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Image 1_Evaluating the efficacy and safety of tebentafusp in the treatment of metastatic uveal melanoma: a 2025 update systematic review and meta-analysis.tif
by: Yanlin Wang (110566)
Published: (2025) -
Image 3_Evaluating the efficacy and safety of tebentafusp in the treatment of metastatic uveal melanoma: a 2025 update systematic review and meta-analysis.tif
by: Yanlin Wang (110566)
Published: (2025) -
Image 4_Evaluating the efficacy and safety of tebentafusp in the treatment of metastatic uveal melanoma: a 2025 update systematic review and meta-analysis.tif
by: Yanlin Wang (110566)
Published: (2025) -
Image 5_Evaluating the efficacy and safety of tebentafusp in the treatment of metastatic uveal melanoma: a 2025 update systematic review and meta-analysis.tif
by: Yanlin Wang (110566)
Published: (2025) -
Image 6_Evaluating the efficacy and safety of tebentafusp in the treatment of metastatic uveal melanoma: a 2025 update systematic review and meta-analysis.tif
by: Yanlin Wang (110566)
Published: (2025)